Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Algenpantucel-L

Known as: Alpha (1,3) Galactosyltransferase Tumor Vaccine, Alpha-1,3-Galactosyltransferase-expressing Allogeneic Pancreatic Tumor Cell Vaccine, Alpha-Gal Pancreatic Cancer Vaccine 
A cancer vaccine comprised of irradiated allogeneic pancreatic cancer cells transfected to express murine alpha-1,3-galactosyltransferase with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
3007 Background: Hyperacute rejection of tissues expressing the carbohydrate α(1,3)Gal xenoantigen is a potent innate immune… Expand
Is this relevant?
Review
2016
Review
2016
Pancreatic adenocarcinoma is the 4th leading cause of cancer death in the USA and the EU. A minority of patients presents with… Expand
Is this relevant?
Review
2016
Review
2016
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death in the United States, and by the year 2020, it is… Expand
Is this relevant?
Review
2016
Review
2016
ABSTRACT Pancreatic adenocarcinoma is notoriously lethal, and despite improvements in systemic chemotherapy approaches bringing… Expand
Is this relevant?
Review
2015
Review
2015
Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and… Expand
  • table 1
Is this relevant?
2014
2014
3029 Background: Algenpantucel-L immunotherapy consists of allogeneic pancreatic cancer cells that have been genetically modified… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BackgroundDespite continued investigation, limited progress has been made in the adjuvant treatment of resected pancreatic cancer… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2011
2011
236 Background: Pancreatic cancer portends a poor prognosis with ∼4% long-term survival. Among the estimated 20% of patients who… Expand
Is this relevant?